Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

View Full Paper
Ask AI
Bookmark
Share

Authors

LLLuca LaninoGUGeoffrey L. UyPDPinkal Desai

Discussion

Loading...

Member takes

Overview

Analysis shows treatment response and survival rates differ by TP53 mutation status in higher risk MDS patients, highlighting risk stratification importance.

Key Points

  • This research aims to evaluate outcomes in patients with higher risk Myelodysplastic Syndromes with TP53 mutations treated with hypomethylating agents and transplant.
  • Analyzed data from 4,732 patients with MDS in the VALIDATE database
  • Assessed biallelic TP53 mutations using WHO, ICC, and CCF classification methods
  • Measured treatment responses using IWG 2023 criteria and evaluated overall survival from HMA initiation
  • TP53 mutations were linked to reduced overall survival compared to wild-type patients, median 11.5 months vs. 23.9 months
  • Treatment response showed higher composite complete remission in TP53 mutation patients post-HMA
  • Unsupervised clustering identified molecular subgroups with different survival rates, aiding refined risk stratification

Cite This Study

Lanino et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d845https://doi.org/10.1182/blood-2025-3863
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT2025 · 1 citations
  2. 2Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study2025 · 1 citations
  3. 3Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy2025
  4. 4Multi-hit TP53 mutation is an independent adverse prognostic factor in allogeneic hematopoietic stem cell transplantation for acute leukemia and myelodysplastic syndromes2025
  5. 5Impact of transplant on <i>TP53</i> <sup>MT</sup> configurational dynamics in myeloid neoplasms.2026